Study

EORTC-1522-QLG

Development of an EORTC questionnaire for individuals at risk for a Hereditary Cancer Predisposition Syndrome : the EORTC QLQ-HCPSxx

Study documentation Back to result

Trial Status

Recruiting

Dates

Date of activation: 15-Dec-2021

Data management at EORTC

None

Design

QoL Module development
Not randomized / N.A.

Study Staff

  • Anne Oberguggenberger (Study Coordinator), A.O Landeskrankenhaus - Innsbruck Universitaetsklinik, Innsbruck
  • Vasilios Vasiliou (Study Coordinator), Bank Of Cyprus Oncology Centre, Strovolos - Nicosia
  • Monika Sztankay (Study Co-Coordinator), A.O Landeskrankenhaus - Innsbruck Universitaetsklinik, Innsbruck
  • Melanie Beauvois (Clinical Operations Manager), EORTC Headquarters, Brussels

Participating groups

  • EORTC Quality of Life Group

Participating centers

  • Helios Klinikum Wuppertal - Klin. Univ. Witten / Herdecke (Wuppertal, Germany)
  • King Hussein Cancer Center (Amman, Jordan)
  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (Amsterdam, Netherlands)
  • Centre Georges-Francois-Leclerc (DIJON CEDEX, France)
  • Queen Elizabeth The Queen Mother Hospital (Margate (Kent), United Kingdom)
  • Maria Sklodowska-Curie National Research Institute of Oncology (Warsaw, Poland)
  • Nicosia General Hospital (Nicosia, Cyprus)
  • UMC-Academisch Ziekenhuis Utrecht (Utrecht, Netherlands)
  • King's College Hospital (London, United Kingdom)